Table 1.
Patient number in total and by sex in major cancer genomic projects
| Project | All cancers | Cancers not arising in sex organsa | ||||
|---|---|---|---|---|---|---|
| Both sexes | Male, n (%) | Female, n (%) | Both sexes | Male, n (%) | Female, n (%) | |
| TCGA | 11 167 | 5346 (47.9) | 5817 (52.1) | 7906 | 4699 (59.4) | 3203 (40.5) |
| ICGC | 24 289 | 13 135 (54.1) | 10 856 (44.7) | 19 301 | 11 700 (60.6) | 7303 (37.8) |
| TARGET | 4866 | 2650 (54.5) | 2177 (44.7) | 4718 | 2568 (54.4) | 2111 (44.7) |
| GENIE | 44 756 | 20 713 (46.3) | 24 025 (53.7) | 32 512 | 17 991 (55.3) | 14 510 (44.6) |
| CPTAC | 1121 | 507 (45.2) | 602 (53.7) | 794 | 507 (63.9) | 287 (36.1) |
Abbreviations: CPTAC, Clinical Proteome Tumour Analysis Consortium; GENIE, Genomics, Evidence, Neoplasia, Information, Exchange; ICGC, International Cancer Genome Consortium; TARGET, Therapeutically Applicable Research to Generate Effective Treatments; TCGA, The Cancer Genome Atlas.
aAll cancer types except those originating in reproductive organs (eg, prostate, uterine, ovary) or in the breast.